Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting.
Chaudhary B, Elkord E. · 2016
Read Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. by Chaudhary B, Elkord E. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5041022.txt.
Introduction
Belal Chaudhary and Eyad Elkord review regulatory T cells in cancer in Vaccines in 2016. Regulatory T cells normally keep the immune system from attacking the body itself. Inside tumors, they can form a shield that blunts anti-tumor attack, and they have become a focus of cancer immune research. The review weighs human evidence on their role in the tumor microenvironment and on ways to target them.
The cells are not one uniform group: distinct subsets settle in tumors and may push outcomes in different directions, which helps explain mixed links with prognosis. Current treatments, including checkpoint drugs, already shift these cells as a side effect. The authors argue that removing or weakening the tumor's own regulatory cells, as part of a combined treatment, could restore anti-tumor immunity. First, though, each subset's exact contribution must be pinned down so healthy tolerance is not broken along with the shield.
Catalog record
| CREATOR | Chaudhary B, Elkord E. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 92 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting By Belal Chaudhary, Eyad Elkord, Theresa L Whiteside Published in: Vaccines DOI: 10.3390/vaccines4030028 ABSTRACT Abstract Recent years have seen significant efforts in understanding and modulating the immune response in cancer. In this context, immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), have come under intense investigation for their proposed roles in suppressing tumor-specific immune responses and establishing an immunosuppressive tumor microenvironment, thus enabling tumor immune evasion. Additionally, recent evidence indicates that Tregs comprise diverse and heterogeneous subsets; phenotypically and functionally distinct subsets of tumor-infiltrating Tregs could contribute differently to cancer prognosis and clinical outcomes. Understanding Treg biology in the setting of cancer, and specifically the tumor microenvironment, is important for designing effective cancer therapies. In this review, we critically examine the role of Tregs in the tumor microenvironment and in cancer progression focusing on human studies. We also discuss the impact of current therapeutic modalities on Treg biology and the therapeutic opportunities for targeting Tregs to enhance anti-tumor immune responses and clinical benefits. Keywords: regulatory T cells, tumor microenvironment, cancer progression, therapeutic targeting, tumor-infiltrating lymphocytes 1. INTRODUCTION Regulatory T cells (Tregs) comprise diverse subsets of immunosuppressive cells that play critical roles in maintaining immune homeostasis and self-tolerance. They are also involved in controlling autoimmunity, infection, graft-versus-host disease, inflammation, fetal-maternal tolerance, and tumor immunity [1]. Tregs are broadly divided by lineage into thymic-derived tTregs, autoreactive T cells selected by high avidity interaction with self-antigens in the thymus, and peripheral pTregs, induced from naïve CD4+ T cells by sub-optimal antigen presentation in the periphery [2]. tTregs are crucial for preserving self-tolerance and preventing autoimmunity, while pTregs maintain peripheral tolerance at mucosal interfaces and in response to external antigens [1,3]. Both subsets of Tregs have traditionally been defined by expression of the Forkhead Box P3 (FoxP3) transcription factor––a “master regulator” of the suppressive lineage—and the IL-2 receptor α chain (CD25) [1,4]. pTregs additionally comprise two FoxP3− subsets with important roles in oral tolerance: Tr1 and Th3 cells [5]. Tregs may exert their suppressive activity via a number of contact-dependent and independent mechanisms, as reviewed extensively [6,7]. Briefly, these include: - Suppressive cytokines (TGF-β, IL-10, IL-35) - Immune checkpoints and inhibitory receptors (CTLA-4, PD-1, LAG-3, TIM-3, ICOS, TIGIT, IDO) - Direct cytotoxicity (perforin/granzyme-mediated) - Metabolic disruption of T effector cell activity (IL-2 consumption) - Induction of tolerogenic DCs, which promote T cell exhaustion and expansion Tregs exhibit considerable phenotypic and functional specialization according to tissue localization, disease state, activation and differentiation status [8,9,10,11]. These subsets play differing roles in disease and health, and may be endowed with one or more of these suppressive mechanisms [12,13]. 2. TREGS IN CANCER In cancers, Tregs are able to suppress anti-tumor immune responses and contribute to the development of an immunosuppressive tumor microenvironment (TME), thus promoting immune evasion and cancer progression [14,15]. Tregs have been extensively characterized in the peripheral blood and immune infiltrates of different cancers [15,16]. An accumulation of FoxP3+ Tregs and, in particular, a higher Treg : T effector cell (Teff) ratio within tumor tissue is associated with worse prognoses in many cancers, including ovarian cancer [17,18], pancreatic ductal adenocarcinoma [19,20], lung cancer [21], glioblastoma [22], non-Hodgkin’s lymphoma [23], melanoma and other malignancies [24,25]. The role of Tregs in immune escape is supported by clinical studies, and numerous in vitro studies, where Treg depletion released anti-tumor immunity. For example, transient Treg depletion induced regression of metastatic lesions in advanced stage melanoma patients [26]. In breast cancer patients undergoing tumor resection and radiotherapy, Treg depletion prior to treatment is associated with an anti-tumor immune response and improved clinical outcomes [27]. Additionally, Treg depletion followed by cancer antigen vaccination generated effective anti-tumor CD4+ and CD8+ T-cell responses in metastatic breast cancer patients [28]. It should also be noted that Treg infiltration and accumulation can correlate with a positive prognosis in certain malignancies, including colorectal and gastric cancers [29,30]. In these cancers, Tregs are proposed to play a protective role by controlling inflammation associated with neoplastic transformation and cancer progression. This topic was recently reviewed [31] and will be briefly discussed. Tregs are able to accumulate within the TME via several mechanisms [32]. These are summarized below: - Recruitment: Tregs are recruited into tumors in response to chemokines secreted by tumor cells and innate immune cells; key chemokine-chemokine receptor combinations include CCL17/22-CCR4, CCL5-CCR5, CCL28-CCR10 and CXCL9/10/11-CXCR3. - Expansion: Tregs can be expanded in situ, and proliferate efficiently in response to tumor-derived factors (TGF-β, IL-10) within the TME. - Conversion: Generation of suppressive Tregs from non-suppressive CD25− conventional T cells (Tconv) driven by tumor-derived transforming growth factor-beta (TGF-β) and adenosine; this has mainly been studied in murine models and the contribution of Treg induction to Treg accumulation within the TME in human cancer remains to be confirmed. Further mechanisms of Treg recruitment and generation are still being uncovered. For example, sphingosine 1-phosphate (S1P)—a bioactive lipid mediator involved in angiogenesis and inflammation—is important for immune cell trafficking and is able to restrain Treg development in the periphery [33]. In pre-clinical models, S1P receptor 1 (S1PR1) signaling was necessary for Treg accumulation within the TME, acting via the JAK/STAT-3 signaling pathway [34]. The importance of S1P/S1P receptor signaling for the immune response in human cancer remains to be confirmed. As highlighted by the variable impact of Tregs in different cancers, the role of Tregs in cancer is multi-faceted and is influenced significantly by cancer type, stage and location, in addition to the unique immune landscape and TME of each cancer [24,25,35,36]. This review focuses on the role of Tregs as suppressors of anti-tumor immune responses, and specifically on their roles within the TME. 2.1. Immunosuppressive Roles of Tumor-Infiltrating Tregs in Cancer Tumor-infiltrating (TI) Tregs play direct roles in promoting immune evasion and the development of a pro-tumorigenic TME. They exhibit distinct phenotypic and functional profiles, upregulating markers associated with activation and enhanced suppressive activity. These include immune checkpoint molecules, cytotoxic T-lymphocyte associated protein 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3/HAVCR2), lymphocyte activation gene-3 (LAG-3), programmed-death 1 (PD-1), inducible T-cell co-stimulator (ICOS), and glucocorticoid-induced TNFR family related gene (GITR); and T cell activation markers, CD25 and CD69 [37,38,39,40,41,42,43,44,45]. Numerous studies have identified suppressive Treg subsets in the peripheral blood of cancer patients. However, direct insights into the suppressive roles of Tregs within the TME are limited. FoxP3+/− TI Treg subsets isolated from primary tumors of colorectal cancer (CRC) patients exerted a potent suppressive activity mediated by TGF-β and IL-10, and also upregulated CTLA-4 and ICOS [44]. In hepatocellular carcinoma (HCC) and pancreatic cancer patients, two distinct FoxP3+/− TI Treg subsets exhibiting differential expression patterns of CTLA-4, PD-1, CD25 and CD69 were identified in tumor-infiltrating lymphocyte (TIL) populations. These TI Tregs suppressed the activity of autologous CD4+ T cells and gamma delta (γδ) T cells via secretion of TGF-β and IL-10 [37,46,47]. In another HCC study, FoxP3−CD69+CTLA-4+PD-1+ Tregs were enriched within the TME where they comprised over 60% of the CD4+ TIL populations and suppressed autologous Teff via membrane-bound TGF-β [43]. FoxP3+ TI Tregs from gastric cancer patients were shown to exert suppressive activity via production of cyclooxygenase-2 (COX-2) and prostaglandin E-2 (PGE-2) [48].